Evonik and Genedata broaden their collaboration with the Genedata Selector biotechnology data management platform
News Sep 22, 2013
Genedata, a leading provider of advanced software solutions for industrial, agricultural, drug discovery, and life science research, has announced that Evonik is extending its collaboration with Genedata. Building on its long-standing partnership with Genedata, Evonik is using the Genedata fully integrated offering that includes Genedata Selector™ for the management and analysis of strain information, scientific data analysis consulting provided by Genedata bioinformatics experts, and specialized IT services. The integrated solution from Genedata will help Evonik advance its industry diversification projects and strengthen the return on its strategic biotechnology investments.
"New, data-intensive and omics-based technologies are catalysts for innovation in the health and food industries," noted Dr. Ralf Kelle, vice president of R&D Bioproducts for the Evonik Health and Nutrition business unit. "Genedata - with its domain expertise in data analysis and management - helps us get maximum value from our data. More importantly, our relationship with Genedata allows us to benefit from their innovative solutions, which contribute to the success of our resource-efficient and sustainable biotechnology research."
Beyond Software - Scientific Data Analysis Consulting & Specialized IT Services
Evonik has successfully used Genedata Selector to manage, visualize, and analyze complete genomes of production strain collections with a focus on mutation analysis and deciphering complex genotype-phenotype relationships. Genedata Selector accelerates difficult strain optimization projects for the production of bio-based chemicals, nutritional proteins, food and feed additives, and cosmetics ingredients.
Now, in addition to Genedata Selector enterprise software, Evonik will also use Genedata scientific data analysis consulting services. Based on in-depth and extensive experience in the industrial biotechnology field, these value-added services help to eliminate resource bottlenecks, provide cost-effective support for strategically important projects, and deliver valuable results quickly and efficiently.
Addressing the complete life cycle of R&D projects - from early-stage feasibility studies to late-stage product development - Genedata scientific data analysis consulting delivers:
proprietary genome annotations, including gene calling and functional annotations up to the pathway level (for prokaryotes as well as eukaryotes);
production strain comparisons, including interpretations of biological effects of variants (e.g. on enzyme activities);
cellular signaling network reconstructions for proprietary strains, based on expression and regulatory sequence data;
biomarkers, based on omics, NGS, pathway, and functional annotation data; and
statistical expression analysis reports (e.g. of microarray or RNAseq data).
In the enterprise R&D environment, Genedata specialized IT services ensure server availability and infrastructure stability for high-performance server infrastructures. These services, which empower researchers to focus more on scientific discovery, include:
hosting and remote server maintenance;
software and database integration services; and
data migration and integration services, including public domain genome release monitoring.
"We are proud of our long-standing and successful partnership with Evonik, a world leader in specialty chemicals," noted Dr. Othmar Pfannes, CEO of Genedata. "Their adoption of the Genedata Selector application suite, coupled with our scientific consulting and professional IT services, serves as an industry model for other customers in industrial biotechnology research who want to leverage the full advantage of our bioinformatics expertise to achieve their business objectives."
LifeArc and Milner Therapeutics Institute Announce a New Partnership in AI for Target DiscoveryNews
LifeArc®, the UK-based medical research charity, and the Milner Therapeutics Institute at the University of Cambridge, today announced a new partnership to identify and validate new drug targets in immuno-oncology and respiratory diseases.READ MORE
Drug-like Compounds Reverse Chemotherapy Failure for 3 Aggressive CancersNews
Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggressive cancers -- ovarian, prostate and breast.READ MORE
Algorithm Unearths Over 1000 Antibiotic Proteins in a Few HoursNews
The algorithm identified 10 times more peptide variations than all previous discoveries combined, aiding the hunt for new antibiotics.READ MORE